Latest Scientific Evidence Stem Cell Technology for No Option CLTI Patients

Описание: Phase II Clinical Data Review: Limb Salvage Outcomes and Clinical Integration of ACP-01 in No-Option CLTI

Addresses the No-Option CLTI Challenge - Despite advances in endovascular techniques and surgical bypass, 30-40% of CLTI patients remain unsuitable for conventional revascularization. These no-option patients face amputation rates approaching 40-50% within one year.

🔔 Be sure to subscribe and tap the notification bell so you don't miss any exciting news and updates!

 🔗 Learn more at www.hemostemix.com
📞 Call us: (905) 580-4170
💬 Share this to raise awareness & reach those in need.
  
🧬Connect with Hemostemix:
💼LinkedIn:   / 3212019  
🗣️Facebook: https://www.facebook.com/profile.php?...
📸Instagram:   / hemostemix.inc  
🌐Website: https://hemostemix.com/
 
⚠️Important: ACP-01 is investigational and not approved by the U.S. FDA. This video is educational only, not medical advice and not a promotion of an unapproved product. Talk to a qualified clinician about your care.
 
📍Florida notice: This Notice Must Be Provided To You Under Florida Law. This physician performs one or more stem cell therapies that have not yet been approved by the United States Food and Drug Administration. You are encouraged to consult with your primary care provider before undergoing any stem cell therapy.

Chapters:
00:00 - Introduction to the webinar and session overview
02:28 - Dr. York Hsiang's background and expertise
03:04 - Limb salvage outcomes and the significance of ACP01
04:28 - Understanding peripheral arterial disease (PAD) and CLTI
06:01 - Symptoms, diagnosis, and severity classification of PAD
09:01 - Natural history of PAD and CLTI progression
12:22 - Epidemiology and risk factors for CLTI
15:02 - Conventional treatments and their limitations in no-option CLTI
18:30 - Defining no-option CLTI and patient categories
21:00 - Stem cell sources and mechanism of angiogenesis via ACP01
23:36 - Safety profile and procedural aspects of ACP01 injections
32:15 - Clinical trial findings: amputation and survival outcomes
35:45 - Wound healing progress and long-term durability
42:33 - Long-term follow-up insights and repeat treatments considerations
44:58 - The impact of monitoring, patient care, and placebo effects
48:58 - Study trends towards FDA benchmarks and future studies
51:06 - Discomfort, injection tolerability, and safety considerations
53:25 - Treatment positioning: last-line versus earlier intervention
54:01 - Regulatory environment and future trial design possibilities
57:38 - The importance of adjunctive wound care and comprehensive management
58:50 - Closing remarks and contact opportunities for further questions